SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.
NYSE New York Stock Exchange
Börse NYSE New York Stock Exchange
ISIN US1488061029
USD
  • Catalent
    Börse NYSE New York Stock Exchange
    ISIN US1488061029 WKN: A112H2
    Symbol CTLT
    USD
  • Catalent
    Börse Börse Frankfurt
    Symbol 0C8
    EUR
  • Catalent
    Börse Börse Berlin
    Symbol 0C8
    EUR
  • CATALENT INC
    Börse Quotrix System der Börse Düsseldorf
    Symbol 0C8
    EUR
  • CATALENT INC
    Börse Gettex System der Börse München
    Symbol 0C8
    EUR
  • CATALENT INC
    Börse Tradegate System der Deutsche Börse AG (60%)
    Symbol 0C8
    EUR
  • CATALENT INC
    Börse Börse Stuttgart
    Symbol 0C8
    EUR
  • Symbol 0C8
ISIN US1488061029
WKN A112H2
Symbol CTLT
Währung USD
Börse NYSE New York Stock Exchange Zeitzone: Europe/Berlin
Firmenname Catalent, Inc
Marktkapitalisierung 17.543.908.768 (+- 11%)

Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:

19.434.817.536 oder 15.653.000.000

Mitarbeiter 16.500 (+- 15%)

Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:

14.000 oder 19.000 Mitarbeiter

KGV 63.25
EBITDA 787.000.000
PEGRatio 3.2529
Buchwert 20.311

Catalent outperformed den DAX um +384 % vom 31.07.2014 bis 24.06.2021

Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 85,5 EUR 0,00% 

Aktionärsstruktur der Catalent, Inc

29 News & Informationen zur Catalent Aktie

  • Cell & Gene Therapy Manufacturing Services Research Report 2021
    prnewswire.com

    Cell & Gene Therapy Manufacturing Services Research Report 2021

    /PRNewswire/ — The “Global Cell & Gene Therapy Manufacturing Services Market by Type (Allogeneic, Autologous, Viral Vector, Non-viral vector), Indication…

  • Global Drug Delivery Systems (DDS) Markets 2021-2027 - Increasing R&D Expenditures Of Innovator Companies And The Trend Of Patent Portfolio...
    thestreet.com

    Global Drug Delivery Systems (DDS) Markets 2021-2027 – Increasing R&D Expenditures Of Innovator Companies And The Trend Of Patent Portfolio Expansion

    DUBLIN, July 29, 2021 /PRNewswire/ — The

  • 2 Stocks Insiders Are Buying
    benzinga.com

    2 Stocks Insiders Are Buying

    When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this …

  • PharmAust makes progress in the quarter as it lays the foundation for commercialisation
    stockhead.com.au

    PharmAust makes progress in the quarter as it lays the foundation for commercialisation

    Special Report: PharmAust has had a busy and productive quarter, setting the foundations for the commercialisation of its lead drug, monepantel.

  • Were Hedge Funds Right About Amcor plc (AMCR)?
    insidermonkey.com

    Were Hedge Funds Right About Amcor plc (AMCR)?

    Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession…

  • Were Hedge Funds Right About Rogers Communications Inc. (RCI)?
    insidermonkey.com

    Were Hedge Funds Right About Rogers Communications Inc. (RCI)?

    The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter,…

  • Monday Sector Laggards: Healthcare, Technology & Communications
    techinvestornews.com

  • Catalent (CTLT) Boosts Portfolio Via Launch of GPEx Lightning
    zacks.com

    Catalent (CTLT) Boosts Portfolio Via Launch of GPEx Lightning

    Catalent's (CTLT) latest product is aimed at improving customer service by speeding up the drug substance development process.

  • Catalent plans $100 mln expansion at vaccine plant in Italy
    financialpost.com

    Catalent plans $100 mln expansion at vaccine plant in Italy

    Catalent Inc plans a $100 million expansion of its plant in Agnani, Italy, where the contract drug manufacturer is currently filling millions of vials of…

  • ETFs with Investments in SP500 Winners of 7
    reddit.com

    ETFs with Investments in SP500 Winners of 7

    Three ETF's per winner (when available) ETF Ticker | % invested in Winner | ETF Full Name Industrials: ETFs investing in Generac Holdings Inc. PRN- …

  • Should I Avoid Expeditors International of Washington (EXPD)?
    insidermonkey.com

    Should I Avoid Expeditors International of Washington (EXPD)?

    In this article we will analyze whether Expeditors International of Washington (NASDAQ:EXPD) is a good investment right now by following the lead of some…

  • Do Hedge Funds Love Affirm Holdings, Inc. (AFRM)?
    insidermonkey.com

    Do Hedge Funds Love Affirm Holdings, Inc. (AFRM)?

    With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred…

  • Global In Vitro Toxicology Testing Market is Estimated to Grow at a CAGR of 11.2% from 2021 to 2030
    globenewswire.com

    Global In Vitro Toxicology Testing Market is Estimated to Grow at a CAGR of 11.2% from 2021 to 2030

    In Vitro Toxicology Testing Market, by Product and Service (Consumables, Assays, Equipment, Software, and Services), Methods (Cellular Assays, Biochemical…

  • Catalent Inc (CTLT): Price Down $-0.42 (-0.38)% Over Past Day, Up $0.25 (0.23)% Over Past Hour
    etfdailynews.com

  • This Therapeutics Company Is Eyeing Zero Competition for the Next 5 Years
    fool.com

    This Therapeutics Company Is Eyeing Zero Competition for the Next 5 Years

    If production setbacks can be avoided, gains should be in sight.

  • Blister Packaging Market Prices will increase by 3%-6% by 2024 | SpendEdge
    prnewswire.com

    Blister Packaging Market Prices will increase by 3%-6% by 2024 | SpendEdge

    /PRNewswire/ — SpendEdge has been monitoring the Blister Packaging will have an incremental spend of 6 Billion during 2020-2024. The report offers an…

  • Catalent (CTLT) to Enhance Its Portfolio via RheinCell Buyout
    zacks.com

    Catalent (CTLT) to Enhance Its Portfolio via RheinCell Buyout

    Catalent (CTLT) expects to strengthen its position in new therapeutic areas and boost its cell therapy portfolio via the latest acquisition.

  • Novo A Buys Spruce Biosciences Inc, Alibaba Group Holding, Kinnate Biopharma Inc, Sells Catalent Inc, Inogen Inc, Inozyme Pharma Inc
    gurufocus.com

    Novo A Buys Spruce Biosciences Inc, Alibaba Group Holding, Kinnate Biopharma Inc, Sells Catalent Inc, Inogen Inc, Inozyme Pharma Inc

    GuruFocus Article or News written by insider and the topic is about:

  • COVID-Impfung ohne Spritze – ein offenes Rennen
    insideparadeplatz.ch

    COVID-Impfung ohne Spritze – ein offenes Rennen

    Wer ein Vakzine zum Schlucken zustandebringt, der knackt den Jackpot. Denn in der armen Welt sind die heutigen Vakzine nicht massentauglich.

  • Khan's Watchlist for 04/12/21-04/16/21 : stocks
    reddit.com

    Khan's Watchlist for 04/12/21-04/16/21 : stocks

    Good morning everyone, here are my new ideas for the next week. As usual, the tickers below don't include the charts with my levels, drawings, and …

  • ACOR Rises On Restructuring, ALXN Pauses COVID-19 Trial, SYBX On Watch
    rttnews.com

    ACOR Rises On Restructuring, ALXN Pauses COVID-19 Trial, SYBX On Watch

    Today's Daily Dose brings you news about Acorda's restructuring; Alexion's decision to pause its COVID-19 trial; and analyst's rating on Synlogic..

  • Contract Development and Manufacturing Organization Industry in APAC to 2030 - Key Drivers, Restraints and Challenges
    markets.businessinsider.com

    Contract Development and Manufacturing Organization Industry in APAC to 2030 – Key Drivers, Restraints and Challenges

    DUBLIN, Jan. 13, 2021 /PRNewswire/ — The 'Asia-Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030…

  • Contract Development And Manufacturing Organization Industry In APAC To 2030 - Key Drivers, Restraints And Challenges
    thestreet.com

    Contract Development And Manufacturing Organization Industry In APAC To 2030 – Key Drivers, Restraints And Challenges

    DUBLIN, Jan. 13, 2021 /PRNewswire/ — The “Asia-Pacific Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category,

  • The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations
    benzinga.com

    The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations

    Here's a roundup of top developments in the biotech space over the last 24 hours.
    Scaling The Peaks
    (Biotech Stocks Hitting 52-week Highs Jan. 12) …

  • Virus Surge Ends Seven Months of U.S. Jobs Growth
    online.wsj.com

    Virus Surge Ends Seven Months of U.S. Jobs Growth

    The U.S. shed 140,000 jobs in December as a resurgence of the virus hit restaurants, ending seven months of job growth and weakening the economy.

  • Looking for a Growth Stock? 3 Reasons Why Catalent (CTLT) is a Solid Choice
    zacks.com

    Looking for a Growth Stock? 3 Reasons Why Catalent (CTLT) is a Solid Choice

    Catalent (CTLT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

  • Moderna : Provides COVID-19 Vaccine Supply Update
    marketscreener.com

    Moderna : Provides COVID-19 Vaccine Supply Update

    Raises lower end of global manufacturing plan for 2021 from 500 million doses previously to 600 million doses

    Continues to invest and hire in order to deliver up to 1 billion doses in 2021
    … | January 4, 2021

  • Global Pharmaceuticals Contract Development & Manufacturing Market (2020 to 2025) - by Service, End-user and Geography
    prnewswire.com

    Global Pharmaceuticals Contract Development & Manufacturing Market (2020 to 2025) – by Service, End-user and Geography

    /PRNewswire/ — The “Global Pharmaceuticals Contract Development & Manufacturing Market (2020-2025) by Service, End User, Geography and the Impact of Covid-19…

  • Covid-19 Vaccines Are in High Demand, but Thousands More Workers Are Needed to Make Them
    online.wsj.com

    Covid-19 Vaccines Are in High Demand, but Thousands More Workers Are Needed to Make Them

    Contract-manufacturing companies working with Pfizer, Moderna and AstraZeneca to accelerate the global availability of coronavirus shots are struggling with a shortage of their own—the staff to meet the production push.

Schreibe einen Kommentar

Wenn du schon einen Account hast, logge dich ein bevor du den Kommentar absendest.

Galue Account Vorteile
  • Battles

    Messe dich mit der Community in Battles.

  • Badges

    Erhalte Belohnungen für Kommentare, die der Community helfen.

  • Mehr Informationen für alle

    Poste Bilder oder Videos zu Themen und Unternehmen und helf dabei, dass Investoren ein kontroverseres Bild erhalten.

  • Kein Datenrisiko

    Du kannst jederzeit deinen Account löschen und gespeicherte Daten einsehen.

Portrait der Catalent Aktie

Das Unternehmen Catalent, Inc aus USA beschäftigt 16.500 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Sonstige Branche, Biotechnologie tätig.

Die Catalent Aktie konnte seit dem 31.07.2014 eine Rendite von bemerkenswerten 450% erwirtschaften.

Das Unternehmen Catalent, Inc ist in mehr als 33 ETFs enthalten und somit eine vermutlich durchschnittlich bekannte Aktie. Der Spitzenreiter VanEck Vectors Pharmaceutical ETF gewichtet Catalent mit 4,57% im ETF.

Es ist auch möglich über Anleihen zu investieren. Hier findest du alle Catalent Anleihen auf einen Blick.

Entdecke die 6 ETFs in denen Catalent, Inc am höchsten gewichtet ist Insgesamt in 33 ETFs enthalten

Dir gefallen die Informationen zu Catalent?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:

Zu Trade Republic

Dir gefallen die Informationen zu Catalent?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:

Zur ING Diba

Dir gefallen die Informationen zu Catalent?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:

Zur Comdirect

Dir gefallen die Informationen zu Catalent?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:

Zu BUX Zero